The endoplasmic reticulum (ER) plays a critical role in protein, lipid, and glucose metabolism as well as cellular calcium signaling and homeostasis. Perturbation of ER function and chronic ER stress are associated with many pathologies ranging from diabetes and neurodegenerative diseases to cancer and inflammation. Although ER targeting shows therapeutic promise in preclinical models of obesity and other pathologies, the available chemical entities generally lack the specificity and other pharmacological properties required for effective clinical translation. To overcome these challenges and identify new potential therapeutic candidates, we first designed and chemically and genetically validated two high-throughput functional screening systems that independently measure the free chaperone content and protein-folding capacity of the ER. With these quantitative platforms, we characterized a small-molecule compound, azoramide, that improves ER protein-folding ability and activates ER chaperone capacity to protect cells against ER stress in multiple systems. This compound also exhibited potent antidiabetic efficacy in two independent mouse models of obesity by improving insulin sensitivity and pancreatic b cell function. Together, these results demonstrate the utility of this functional, phenotypic assay platform for ER-targeted drug discovery and provide proof of principle for the notion that specific ER modulators can be potential drug candidates for type 2 diabetes.
INTRODUCTION
The endoplasmic reticulum (ER) is a central organelle for the synthesis of proteins and lipids and is a critical regulator of cellular calcium signaling and homeostasis (1) . Within the ER, protein synthesis and secretion processes are tightly and dynamically regulated at many levels to meet intrinsic needs as well as external demands (2) . In general, the rate of protein synthesis is balanced with the ER protein-folding capacity to avoid accumulation of unfolded protein intermediates inside the ER lumen. When the rate of synthesis exceeds the folding capacity, unfolded proteins accumulate in the ER, triggering the unfolded protein response (UPR) (3) .
Three ER transmembrane proteins act as sensors of unfolded protein accumulation in the ER: PKR (RNA-activated protein kinase)-like endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1) (4) (5) (6) (7) . Upon activation, PERK phosphorylates the translation initiation factor eIF2a (eukaryotic initiation factor 2a), reducing the rate of new protein synthesis (7) . IRE1 is a kinase with RNA ribonuclease activity; in response to ER stress, it dimerizes, undergoes autophosphorylation, and cleaves the X-box binding protein 1 (Xbp-1) mRNA (8) (9) (10) . The translated product of this cleavage event (sXbp-1) is an active transcription factor that promotes the expression of genes that encode protein chaperones to enhance protein folding and other gene products that support ER biogenesis (11) . Similarly, in the absence of ER stress, ATF6a is repressed through its luminal domain by binding to ER chaperones such as glucose-related protein 78 (GRP78). The accumulation of unfolded proteins under stressful conditions displaces GRP78 from ATF6a, which, in turn, unmasks the ATF6 Golgi localization sequence and subsequently releases ATF6 from the ER. In the Golgi, ATF6a is processed by proteases that liberate its cytoplasmic domain (12, 13) , allowing it to translocate to the nucleus to regulate target gene transcription (11) . Together, these three canonical branches of the UPR restore the balance between protein synthesis and folding by inhibiting translation to decrease global protein synthesis, increasing degradation and disposal of unfolded protein intermediates from the ER, and increasing the folding capacity of the ER by expanding its volume and increasing chaperone synthesis (14) (15) (16) . However, when the ER is chronically compromised, prolonged ER stress leads to the initiation of multiple additional cellular stress and inflammatory pathways via activation of the protein kinases JNK (c-Jun N-terminal kinase) and PKR (17) (18) (19) as well as other cell signaling proteins (20) . Under acute and severe ER stress conditions, the cell might even be committed to apoptosis through the up-regulation of CHOP (C/EBP homologous protein) and other pathways (21, 22) .
It has been well established that chronic ER stress is not sustainable, results in a defective UPR and other adaptive responses, and is strongly associated with a variety of pathologies including neurodegenerative diseases, cancers, and metabolic syndrome (20, (23) (24) (25) . Whereas some of these pathologies relate directly to the canonical functions of the ER, in recent years, emerging evidence has demonstrated that, in the metabolic context, ER-associated signaling networks also engage gluconeogenic and lipogenic pathways, impair hormone action, and influence systemic metabolic homeostasis, thus establishing the ER as a critical metabolic and immunometabolic hub that regulates cell function in health and disease states (20) . Therefore, corrective measures that target ER function and UPR capacity represent an attractive therapeutic strategy for many metabolic and other diseases (24, 26, 27) .
In support of this hypothesis, small molecules with chemical chaperone activity such as 4-phenyl butyric acid (PBA) and tauroursodeoxycholic acid (TUDCA) have been successfully applied in rodent models of metabolic disease to modulate ER responses and to improve systemic metabolism (28) (29) (30) (31) . PBA and TUDCA have also been tested in limited, proof-of-principle human studies and demonstrate similar activities, including increasing insulin sensitivity, preventing lipotoxicity, and improving pancreatic b cell function (insulin production) (32, 33) . However, because the chemical chaperones were not identified by direct screening of ER function, they might lack mechanistic specificity and have limited success in clinical applications because of the requirement for high doses and prolonged treatment (34) .
As one approach to overcome these issues, there have been recent efforts to use small molecules to chemically block the activity of individual UPR sensors to modulate downstream effects, which may produce opportunities for therapeutic use under certain conditions such as cancer (35, 36) . Preconditioning with low-dose chemical ER stress inducers has also been shown in cell culture and some in vivo models to boost ER function in the long term by engaging the UPR pathways (37) (38) (39) , but these noxious toxins are unlikely to have any clinical utility. Hence, there is a general scarcity of molecular or chemical tools to modulate ER capacity and, thus, the UPR for exploratory or therapeutic applications, and there are no functional screening platforms to search for such chemical entities. Here, we report the development of phenotypic assay platforms that enabled us to search for alternative molecules that modulate ER protein-folding capacity. Using these systems, we identified and characterized a small molecule with the capacity to protect ER function in vitro and exert potent antidiabetic effects in vivo.
RESULTS
Complementary high-throughput, functional assay systems permit real-time, continuous measurement of ER protein-folding activity and reserve capacity One of the key obstacles in the field of ER-based therapeutics is the lack of quantitative assay systems with a sufficient dynamic range to directly monitor ER function, which we define as the capacity of the ER to handle challenges to its functional capacity such as the influx of unfolded proteins into the ER lumen. We attempted to tackle this obstacle by using components of well-established interactions in the ER lumen that occur during the UPR or secreted protein folding to construct high-throughput screening platforms. In two independent assays, we used secreted reporters and integrated internal controls for general processes that are regulated during the UPR (such as protein synthesis or secretion) and designed the assays such that their readouts occurred in opposite directions to control for nonspecific regulatory events.
The luminal domain of one of the main UPR sensors, ATF6a, binds to the ER chaperone GRP78, which contributes to its ER retention and the silencing of ATF6a transcriptional activity under nonstressful conditions (12) . Therefore, we fused a human gene fragment that encodes a peptide derived from the ATF6a luminal domain (ATF6LD) to a reporter gene from Cypridina noctiluca that encodes luciferase (Cluc), driven by the cytomegalovirus (CMV) promoter, to measure the free chaperone content and reserve capacity of the ER. We hypothesized that cells with abundant chaperone expression would retain the ATF6LD-Cluc fusion protein in the ER and thus display a low level of luciferase secretion, whereas reduced chaperone expression should liberate this chimeric protein from the ER, resulting in a high level of luciferase secretion into the medium over time (Fig. 1A) . Indeed, in human embryonic kidney (HEK) 293 cells that stably expressed the ATF6LD-Cluc reporter, small interfering RNA (siRNA)-mediated suppression of GRP78 expression resulted in a greater than twofold increase in luciferase secretion (Fig. 1B) . Similarly, treatment of these cells with the chemical ER stress inducer thapsigargin increased ATF6LD-Cluc secretion in a dose-dependent manner because higher concentrations of thapsigargin decreased chaperone availability (Fig. 1C) . As predicted, in cells that expressed the ATF6LD-Cluc construct, immunoprecipitation with a Cluc antibody demonstrated direct interaction between the fusion protein and GRP78, and this interaction was reduced after treatment with thapsigargin ( fig. S1A ). As an internal control, the reporter construct also contained a gene that encodes a second secreted luciferase, Gaussia luciferase (Gluc), whose expression was driven by a separate CMV promoter. The secretion of the readily folded Gluc was not affected by GRP78 suppression or by thapsigargin treatment ( fig. S1B and Fig. 1C ), suggesting that ATF6LD-Cluc secretion is a quantitative and inverse indicator of ER free chaperone content and reserve capacity.
Then, we built on our knowledge that the membrane protein asialoglycoprotein receptor 1 (ASGR1) is a slow-maturing protein whose secretion is decreased under ER stress conditions such as in the setting of obesity (17) . Interventions that correct ER function in obese liver result in higher levels of ASGR1 production, indicating that ASGR1 concentration is sensitive to ER function and directly reflects a response to metabolic challenges that compromise the ER in obesity (17) . To take advantage of these properties, we constructed an ASGR-Cluc fusion protein to monitor ER folding capacity (Fig. 1A ). For this, we used the same backbone that was used for the aforementioned reporter but replaced the ATF6LD-derived cassette with the mouse Asgr1 gene sequence deprived of its membrane-anchoring domain and fused to the Cluc gene. In this system, we predict that compromising ER homeostasis will lead to less efficient protein folding and, therefore, lower levels of secretion of the ASGR-luciferase fusion protein (ASGR-Cluc). Indeed, reducing ER folding capacity by siRNA-mediated suppression of GRP78 decreased ASGR-Cluc secretion by 50% (Fig. 1D) . Similarly, thapsigargin-induced chemical ER stress also reduced ASGR-Cluc secretion in a dose-dependent manner (Fig. 1E ). This construct also included a Gluc reporter as an internal control, and secretion of Gluc was not altered by GRP78 suppression or thapsigargin treatment ( fig. S1C and Fig. 1D ), indicating that ASGR-Cluc is a specific and quantitative reporter of ER protein-folding capacity. Together, these data validated the informative value of these reporters in examining ER functional capacity.
Azoramide is a dual-function ER modulator Development of the ASGR-Cluc and ATF6LD-Cluc reporters provided the opportunity to directly and quantitatively measure ER proteinfolding activity and chaperone capacity in live cells. First, we evaluated the potential ER modulating capacities of small molecular compounds identified on the basis of their ability to engage the UPR in the absence of cellular toxicity. One of these, N-{2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl} butanamide ( Fig. 2A , referred to hereafter as azoramide), activated, in a dose-dependent manner, luciferase reporter genes whose expression was driven by the cellular UPR response element (UPRE) and the ER stress response element (ERSE) ( fig. S2 ). Consistent with this activity, exposure to azoramide transiently and dose-dependently induced the expression of several chaperone genes, including those that encoded GRP78 and DNAJC3 (Fig. 2 , B and C), and induced phosphorylation of eIF2a (Fig. 2C ). However, these effects occurred to a significantly lesser degree than that observed with thapsigargin treatment, and remarkably, even at quite high doses (25 mM), azoramide treatment did not lead to increased expression of the proapoptotic CHOP or GADD34 proteins (Fig. 2 , B and C). These data suggest that azoramide might have the protective effects of enhancing chaperone expression and reducing protein synthesis without inducing cytotoxicity and apoptosis. Next, we used our functional assay systems to investigate the potential cytoprotective benefit of this small-molecule modulator of ER function. Treatment with azoramide for 4 hours dose-dependently increased ASGR-Cluc secretion (Fig. 2D) . In this setting, thapsigargin treatment markedly suppressed ASGR reporter activity (Fig. 1F) , whereas both agents increased the expression of chaperones. These data illustrate that, unlike a chemical ER stress inducer, azoramide acutely enhances the protein-folding capacity of the ER. In the ATF6LD-Cluc assay, we found that 24-hour treatment with azoramide decreased ATF6LD-Cluc secretion (Fig. 2E) . Furthermore, overexpression of chaperones resulted in a marked decrease in ATF6LD-Cluc secretion that was not further affected by azoramide treatment (Fig. 2F) , suggesting that increased chaperone expression may mediate the azoramideinduced block of ATF6LD-Cluc secretion. siRNA-mediated inhibition of individual chaperones was insufficient to block the effect of azoramide on ATF6LD-Cluc secretion ( fig. S3A ), indicating that the expression of multiple chaperones or changes in total chaperone capacity might underlie this effect, as would be predicted to be monitored by this readout.
We next asked whether activity of a specific UPR branch was required for the azoramide effect on ATF6LD-Cluc secretion. In the absence of azoramide, suppression of XBP-1 resulted in a potent increase in ATF6-Cluc secretion, whereas reducing the level of ATF6a resulted in a mild decrease in reporter activity ( fig. S3B ). However, reducing expression of XBP-1 and PERK abrogated the effect of azoramide, whereas suppression of ATF6a appeared to have no effect (Fig. 2G ). In agreement with these observations, treatment of the stably transfected HEK293 cells with the PERK inhibitor GSK2606414 or the IRE1 inhibitor 4m8C completely abrogated the effect of azoramide on ATF6LD-Cluc secretion (Fig. 2H ). These data suggest that azoramide might require the presence of intact IRE1 and PERK branches of the UPR to fully increase chaperone capacity. Together, these experiments identify azoramide as a new class of compound with the dual property of boosting ER protein folding acutely and activating ER chaperone capacity chronically to promote ER homeostasis.
Azoramide protects cells from induced ER stress
Because azoramide induced chaperone capacity and improved ER function, we next asked whether these effects could protect cells against ER stress conditions. Tunicamycin is a chemical compound that blocks protein glycosylation and causes the accumulation of misfolded proteins in the ER. Treatment of reporter cells with tunicamycin dose-dependently increased ATF6LD-Cluc secretion and decreased ASGR-Cluc secretion (Fig. 3A, black lines) , consistent with the known deleterious effect of this chemical on ER function. Co-treatment of azoramide and tunicamycin diminished the ER stress-induced reduction in ER protein-folding capacity and chaperone abundance (Fig. 3A , orange lines), and 5 hours of pretreatment with azoramide was sufficient to nearly abrogate the effect of tunicamycin, as reflected in the patterns of ATF6LD-Cluc and ASGR-Cluc secretion (Fig. 3A, red lines) . Suppression of chemically induced stress was also observed in the stably transfected HEK293 cells that overexpressed GRP78 ( fig. S4 ), further supporting our hypothesis that the protective effect of azoramide treatment is related to induced chaperone capacity.
The cytoprotective effects of azoramide pretreatment were also evident biochemically. Treatment of human hepatoma HuH7 cells with tunicamycin in the absence of azoramide markedly induced GRP78 and CHOP protein expression, but pre-and co-treatment with azoramide protected cells from CHOP induction (Fig. 3B) . The changes in CHOP and GRP78 protein levels were reflected in the transcript level of their encoding genes upon azoramide and tunicamycin treatments ( fig. S5 ), indicating the prevention of the response typically elicited by tunicamycin treatment. In HuH7 cells pretreated with azoramide, exposure to tunicamycin resulted in a markedly reduced induction of GRP78 protein expression compared to untreated controls, indicating a lower overall level of ER stress in pretreated cells (Fig. 3B) . These data provide molecular and functional evidence that azoramide treatment potently protects cells against chemically induced ER stress conditions.
We also examined the potential of azoramide to protect cells against two additional physiological models of ER stress. First, we expressed the ATF6LD-Cluc reporter in HEK293A cells and transitioned the cells from 21 to 1% O 2 to trigger hypoxia-induced ER stress. Hypoxia induced a significant increase in ATF6LD-Cluc secretion, which was completely prevented by pretreatment with azoramide (Fig. 3C) . Next, we analyzed ER stress and cell survival in HEK293A cells transfected with a vector that expressed a mutant form of the rhodopsin protein (P23H). The P23H rhodopsin mutant is a misfolding form of the protein that has been identified in patients with autosomal dominant retinitis pigmentosa (40) ; accumulation of this misfolded protein activates the UPR in retinal cells (41) , and in an animal model of the disease, vision can be restored by overexpression of GRP78 (42) . We found that expression of mutant rhodopsin significantly induced CHOP expression, and, after treatment with the proteasome inhibitor MG132 to enhance accumulation of the misfolded protein, P23H rhodopsinexpressing cells exhibited significantly reduced viability. Remarkably, these effects were dose-dependently ameliorated by treatment with azoramide (Fig. 3, D and E) , indicating the broad protective effects of this compound against ER stress arising from various etiologies.
A critical component of ER function under all conditions is the ability to preserve calcium stores, because calcium plays a critical role in promoting protein folding and ER homeostasis (43) . Hence, we examined whether the broad impact of azoramide on ER function included mechanisms related to intraluminal calcium levels by expressing an ER-targeted Ca 2+ fluorescence resonance energy transfer (FRET) reporter in a mouse hepatoma cell line (Hepa 1-6 cells) and treating the cells with azoramide. As depicted in Fig. 4 (A and B) , azoramide treatment modestly but significantly increased baseline ER Ca 2+ levels. Furthermore, in control cells, thapsigargin treatment induced rapid Ca 2+ release from the ER, as measured by a decline in the FRET ratio (slope), whereas azoramide-pretreated cells retained a greater fraction of Ca 2+ in the ER (lag time) (Fig. 4C) .
In a complementary approach, we measured the thapsigargininduced Ca 2+ rise in the cytosol using the fluorescent dye Fura-2. In accordance with the observed improvement of ER calcium retention, azoramide treatment induced a higher cytosolic Ca 2+ peak after thapsigargin stimulation compared to control (Fig. 4, D and E) . These data indicate that azoramide-mediated protection against chemically induced ER stress is reflected by enhanced calcium retention in the ER, thus increasing ER calcium concentrations. To understand this effect further, we asked whether azoramide treatment altered expression of enzymes required to maintain the high ER-cytoplasmic Ca 2+ concentration gradient. Indeed, azoramide treatment of a hepatocyte cell line induced a significant increase in protein levels of the sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase (adenosine triphosphatase) (SERCA) (Fig. 4F ), indicating that azoramide's mechanism of action in ER calcium retention involves, at least in part, enhancement of SERCA activity, which is disturbed in obesity and diabetes (17) .
Azoramide improves glucose homeostasis in mice with genetic obesity
The identification of azoramide as a compound with the dual properties of acutely promoting ER folding and boosting long-term ER reserve capacity suggested that it may harbor activity as an ER-based therapeutic agent. We first chose to study the effect of azoramide in a genetic model of severe obesity and diabetes (ob/ob mice) because of the wellestablished involvement of ER dysfunction in disease pathogenesis in both experimental models and humans as well as the mechanistic connection between ER stress and glucose metabolism (19, (44) (45) (46) (47) (48) (49) (50) (51) . Similar to our observations in cell culture, daily oral administration of azoramide (150 mg/kg) for 1 week resulted in improved ER function in the liver, as evidenced by induced expression of GRP78 (Fig. 5A ). This brief treatment did not alter body weight (Fig. 5B) but was sufficient to significantly improve fasting glucose (Fig. 5C ) and glucose tolerance (Fig. 5D ). In addition, azoramide was well tolerated; 5 weeks of dosing did not induce weight loss ( fig. S6A ) but did result in significantly reduced fasting glucose ( fig. S6B ) and markedly improved glucose tolerance ( fig. S6C) . Furthermore, the early induction of GRP78 in liver lysates was no longer apparent after 5 weeks of treatment ( fig. S6D ), supporting the conclusion that ER protein-folding capacity was improved in this setting.
Azoramide preserves b cell function and survival during metabolic ER stress We next asked whether the azoramide-induced improvement in glucose homeostasis in obese mice also involved improved pancreatic b cell function or survival, because these insulin-producing cells are susceptible to ER stress in the setting of increased insulin demand (52) (53) (54) . In pancreatic islets isolated from ob/ob mice treated with azoramide for 10 days, we observed higher levels of expression of insulin pre-mRNA and pancreatic and duodenal homeobox 1 (Pdx1) (Fig. 6A) relative to untreated mice, potentially indicating an azoramide-driven improvement in b cell function. In vehicle-treated ob/ob mice, glucose-stimulated insulin secretion (GSIS) was absent, and there was a trend toward decreased circulating insulin 15 min after mice were given the glucose bolus (Fig. 6B) . However, 1 week of azoramide treatment significantly improved in vivo GSIS in the ob/ob model (Fig. 6B) . To further investigate the b cell-intrinsic effects of azoramide, we used pancreatic b cell lines. In mouse MIN6 b cells, azoramide treatment significantly rescued the blunted GSIS observed in the setting of palmitate-induced ER stress ( Fig. 6C) , and in the rat insulinoma cell line INS-1, azoramide treatment improved viability in the setting of glucose and lipid-induced toxicity (Fig. 6D ). These results demonstrate that the metabolic improvements observed with azoramide treatment might be mediated, at least in part, by improvements in b cell function and survival.
Azoramide improves glucose homeostasis in mice with diet-induced obesity Observing these marked effects on glucose metabolism prompted us to perform more detailed metabolic analysis in an additional model with diet-induced obesity, a mouse model that is more relevant to human disease and also characterized by ER stress (46-49, 55, 56) . Male mice fed a 60% high-fat diet (HFD) for 20 weeks were treated with azoramide (150 mg/kg) by gavage once per day for 1 week (performed at the University of Massachusetts national mouse metabolic phenotyping center). This brief treatment was sufficient to markedly improve fasting blood glucose (Fig. 7A ) and reduce body weight (Fig. 7B) . Hyperinsulinemic euglycemic clamps were then performed in these mice to determine whole-body glucose fluxes and examine target tissues influenced by this treatment. There was a marked increase in the glucose infusion rate in mice receiving azoramide (Fig. 7C) , resulting in significantly elevated glucose disposal rates (Fig. 7D) . Hepatic glucose production during the clamp was also markedly reduced (Fig. 7E) . Under the clamp conditions, insulin essentially completely suppressed hepatic glucose production in the azoramide-treated group. Consistent with the increased rates of disposal, glucose uptake to peripheral tissues, such as muscle (Fig. 7F ) and white adipose tissue (Fig. 7G) , was significantly increased by azoramide, as was the rate of glycogen synthesis (Fig. 7H) , demonstrating increased insulin action in liver and in peripheral tissues. Together, these data suggest that systemic administration of azoramide has potent insulin sensitizing and antidiabetic properties in multiple preclinical models of obesity and that these effects are readily reproducible by independent facilities and scientists.
DISCUSSION
Chronic ER stress and a defective UPR are important mechanisms in the pathogenesis of metabolic diseases (20) . In human patients, aberrant ER function and defects in the UPR are features of obesity and both type 1 and type 2 diabetes (30, 49-51, 53, 57-59) . Therefore, interventions that target ER function or are designed to improve the UPR capacity may be useful therapeutic strategies for metabolic and other pathologies. A few studies in human patients using chemical chaperones provide proof of principle that such interventions have translational implications (32, 33). However, there are limitations associated with these existing chemical entities (such as lack of specificity and toxicity with long-term use) and a shortage of strategies, including cellular assay systems, by which to identify and develop a diverse set of new and more effective molecular entities. Here, we used a new screening platform with reporter assays that measure ER function to characterize azoramide, a small-molecule UPR regulator. Azoramide displayed the unique property of acutely increasing ER protein-folding output while chronically inducing chaperone expression and promoting ER homeostasis. Treatment of cells with azoramide was strongly protective against chemical (thapsigargin-and tunicamycin-induced), hypoxia-, lipotoxicity-, and protein misfolding-induced ER stress. Further, azoramide treatment significantly improved insulin sensitivity, glucose tolerance, and b cell function in multiple obese mouse preclinical models. These data provide proof of principle that small-molecule modulators of adaptive UPR pathways can be identified with functional phenotypic screens targeting the ER and confer benefit in the treatment of ER stress-mediated pathologies. Azoramide was also effective in preventing the death of cells that expressed a mutant form of rhodopsin identified in autosomal dominant human retinitis pigmentosa and associated with protein misfolding and ER stress (41) . Because azoramide protected these cells from death, it may represent a therapeutic opportunity against forms of progressive neurodegenerative disorders, including retinitis pigmentosa, that feature cell death induced by mutated misfolding proteins. Furthermore, our approach to identifying therapeutic candidates opens up the possibility of discovering similar compounds that alleviate ER stress by capitalizing on the adaptive features of the UPR.
Currently, two strategies guide the development of ER-based therapeutics. The first is preconditioning. For example, a subtoxic dose of classical ER stress inducers has been shown to protect against oxidative stress in cell lines (37) , prevent cell death in response to nephrotoxins (38) and methylmercury (39) , and prevent the development of immune-mediated nephritis (60) and vascular leakage (61) in mouse models. The second strategy is the use of chemical chaperones (62) . Smallmolecule chemical chaperones such as PBA and trimethylamine N-oxide dihydrate relieve ER stress by aiding protein folding in the ER lumen (63) . These molecules and other chemical chaperones such as TUDCA improve glucose homeostasis in a mouse model of diabetes (28) and might be therapeutic in humans (32, 33) . Recently, a new class of ER stress-relieving smallmolecule chemical chaperones was identified by a high-throughput chemical screen for inhibitors of GRP78 promoter-driven luciferase expression (64) . However, the common feature of all these chemical chaperones is that they blunt the UPR pathways, as evidenced by decreased GRP78 protein expression. As demonstrated herein, azoramide has distinct advantages over both the preconditioning and chemical chaperone approaches. First, unlike chemical toxins, azoramide pretreatment did not impair ER function as part of its initial action. Second, azoramide was effective at much lower concentrations than those of chemical chaperones, with the added benefit of engaging endogenous ER homeostasis-resolution programs. The remarkable potency of azoramide as an antidiabetic agent also raises the potential utility of the functional screening systems described here to generate additional such molecules to target metabolic diseases.
Maintaining a high calcium concentration in the ER is critical for various ER functions, such as protein folding and secretion. Calcium can bind to some amino acid side chains and thus may directly alter protein folding; also, calcium is required for the function of multiple chaperones, including GRP78 (65) . The high luminal calcium concentration is established by a balance between calcium uptake via the action of SERCA enzymes and calcium release by inositol 1,4,5-triphosphate (IP 3 ) receptors (66) , and it was shown previously that reducing ER calcium release by the IP 3 receptor improves glucose homeostasis in obese diabetic mice (67, 68) . We recently demonstrated that SERCA activity is compromised in the livers of genetically obese mice, resulting in reduced Ca 2+ storage in the ER lumen (17) . Here, we show that azoramide treatment leads to increased SERCA expression, resulting in enhanced retention of Ca 2+ within the ER. Thus, it is possible that the induction of chaperone gene expression in vitro and the antidiabetic effect of azoramide in obese mice are related (directly or indirectly) to the modulation of calcium homeostasis. Our efforts to dissect this molecular mechanism indicate that azoramide interacts with UPR pathways to promote resolution of ER stress and improve ER function. Specifically, genetic suppression and chemical inhibitor experiments suggest that the PERK and IRE1/XBP-1 arms of the UPR are involved in azoramide action, although at this time, it is unclear whether the effects of azoramide result from direct interactions with these ER sensors and to what extent its actions are dependent on an intact UPR system. In summary, the high-throughput functional assay platform described here demonstrates the feasibility to monitor ER function and identify potent molecular entities that act on the ER and are effective in the treatment of diabetes in preclinical models. These systems should facilitate the efforts to chemically target ER stress and identify small molecules that may have utility in many other disease states.
MATERIALS AND METHODS

Study design
The objective of the study was to develop assays to dynamically monitor ER function and to characterize the cellular and physiological effects of a small-molecule modulator of ER function. For the in vitro experiments, the dose-response curves for reporter assays were performed in duplicate; quantitative real-time polymerase chain reaction (PCR) samples were analyzed in technical and experimental duplicates. All of the experiments were performed at least twice. In vivo experiments were performed twice in independent cohorts. All in vivo experiments [glucose tolerance test (GTT), insulin tolerance test, and blood glucose measurements] were performed blinded. The elimination criteria for the outliers were based on the visible health of the individual mice. Mice appearing sick or that underwent significant weight loss were eliminated from analysis.
Biochemical reagents
Azoramide was synthesized at Syncore Laboratories (Shanghai, China), the details of which are described in fig. S7 . Tunicamycin and thapsigargin were obtained from Sigma. Lipofectamine, siRNAs, RNAiMax, and TaqMan primers and probes were from Life Technologies. Short hairpin RNA constructs were from Sigma. Cypridina luciferin and native coelenterazine (CTZ) were procured from Prolume Ltd.
Reporter construction
Functional reporter plasmids pGluc/ATF6LD-Cluc and pGluc/ASGRCluc were generated as follows: full-length coding sequence of Cypridina luciferase (Cluc) (GenBank accession no. AB159608) protein was cloned in a pCDNA3.1(−) cloning plasmid (Invitrogen, catalog #V795-20) between Nhe I and Xba I restriction sites downstream of a CMV promoter. Then, the Gluc (GenBank accession no. AY015993) coding sequence controlled by CMV promoter (CMV-Gluc) was cloned using an Mfe I restriction site using PCR primers (forward, TGCTTAGGGTTAGGCGTTTT; reverse, TGGCAAGTGTAGCGGTCA). ATF6LD (amino acids 400 to 670) of human ATF6a protein (GenBank accession no. AAB64434.1) was cloned inside Cluc gene (GenBank accession no. AB159608) after signal peptide sequence using primers (forward, CAGGATTCCAGGAGAATGAA; reverse, AGGACAGTCCTGTGTGCCTC) to generate ATF6LD-Clucexpressing plasmid pGluc/ATF6LD-Cluc. ASGR coding sequence (amino acids 62 to 284) of mouse ASGR1 protein (GenBank accession no. NP_033844.1) was cloned inside Cluc gene after signal peptide sequence using primers (forward, AATTCCCAACTCCGGGAAGA; reverse, ATTAGCCTTATCCAACTTTGTCTCA) to generate ASGRCluc-expressing plasmid pGluc/ASGR-Cluc.
Cell line experiments
Compound treatment of reporter-expressing HEK293 cells was performed in 96-well plates. The cells were seeded before the treatment at a density of 1.5 × 10 4 cells per well. The next day, the cells were changed to a fresh medium containing various concentrations of compounds. At the end of the treatment, 10-ml medium was transferred to two 96-well white plates for luciferase assays following the manufacturer's protocol. Briefly, 50 ml of luciferase substrate (1 mM Cypridina or 10 mM CTZ in 100 mM tris buffer, pH 7.5) was added to the 10-ml medium and incubated in the dark for 5 to 10 min. The luminescence was read on EnVision plate reader (PerkinElmer).
Inducible ATF6LD-Cluc reporter cells were generated using TetExpress Inducible Expression System (Clontech). The cells were induced overnight according to the manufacturer's protocol and incubated in either normoxia (21% O 2 ) or hypoxia (1% O 2 ) (H35 Hypoxystation, Don Whitley Scientific) for 16 hours. Luminescence was read as described above.
HEK293A cells were transfected with Bovine Rhodopsin WT , Rhodopsin P23H (a gift from M. Cheetham, University College London Institute of Ophthalmology), or GFP control plasmids using FuGENE HD. Eight hours after transfection, cells were washed with fresh medium and treated with azoramide or vehicle. For gene expression analysis, cells were harvested after 24 hours. For viability analysis, 1 mM MG132 was added to the medium 16 hours after transfection. Twenty-four hours after treatment, cells were analyzed using the CellTiter-Glo Luminescent cell viability assay system (Promega) following the manufacturer's protocol.
INS-1 cells were treated with 25 mM glucose and 500 mM palmitate in the absence or presence of 20 mM azoramide for 60 hours. At the end of the incubation, viability was measured using the CellTiter-Glo cell viability assay system.
Analysis of GSIS
Insulin release from MIN6 cells was measured as previously described (69) . Briefly, MIN6 cells treated with bovine serum albumin (BSA) or 200 mM palmitate with or without azoramide for 48 hours were preincubated for 30 min in Krebs-Ringer bicarbonate (KRB) buffer containing 2.8 mM glucose and 0.2% BSA, after which they were incubated for 1 hour with KRB buffer containing either 22.4 or 2.8 mM glucose and 0.2% BSA. The secreted insulin was analyzed using an enzyme-linked immunosorbent assay system (Crystal Chem).
ER calcium measurements ER calcium levels were determined using the D1ER (cameleon) calcium sensor provided by R. Tsien (University of California, San Diego) as previously described (68) . Briefly, Hepa 1-6 cells were seeded on 3.5-cm imaging dishes and transiently transfected with D1ER plasmid using Lipofectamine. Twelve hours after transfection, cells were treated with 20 mM azoramide compound or DMSO (vehicle) for 48 hours in growth medium (Dulbecco's modified Eagle's medium, 10% cosmic calf serum). For imaging, cells were washed and maintained in a medium as follows: 10 mM Hepes, 150 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM D-glucose (pH 7.4). Ca 2+ -free medium was based on the formula above, in the absence of CaCl 2 and adding 2 mM EGTA and 3 mM MgCl 2. Fluorescent images of single cells were obtained using an Olympus IX81 microscope and an ORCA-AG camera from Hamamatsu Photonics with a filter cube Chroma 71007A. Emission ratio of the cameleon was obtained using two emission filters (485/40 for cyan fluorescent protein and 535/25 for citrine) controlled by a Lambda 10-2 filter changer (Sutter Instruments). Exposure times were typically 250 ms, and images were collected every 5 s, background-corrected, and analyzed with SlideBook (Intelligent Imaging Innovations).
Cytosolic calcium measurements
Cytosolic Ca 2+ levels were determined using Fura-2 AM (Invitrogen) as previously described (68) . Briefly, cells were loaded with 4 mM Fura-2 AM and 1 mM Pluronic F-127 in Hanks' balanced salt solution for 60 min at room temperature and then washed and maintained in the same buffer as described for ER Ca 2+ measurements. Fluorescence images were obtained using an Olympus IX70 with 40× objective and alternately illuminated with 340-and 380-nm light for 250 ms (Lambda DG-4; Sutter Instrument Co.). Emission light >510 nm was captured using a chargecoupled device camera (ORCA-ER; Hamamatsu Photonics). Images were collected every 5 s, background-corrected, and analyzed with SlideBook (Intelligent Imaging Innovations).
Mice
All animal care and experimental procedures were performed under approval of animal care committees of Harvard University. Male mice with genetic obesity were obtained from Jackson Laboratories (strain: B6.Cg-Lep ob /J, stock no.: 000632) at 9 to 12 weeks of age and kept on regular chow diet. Male mice for the diet-induced obesity model (HFD) were also obtained from Jackson Laboratories (strain: C57BL/6 J DIO, stock no.: 380050), which were fed ad libitum for 20 weeks with 60% kcal fat diet (D12492i, Research Diets) after weaning. The mice were kept on a 12-hour day/night cycle, and azoramide compound was fed to mice once a day at 3:00 p.m. by oral gavage (150 mg/kg in 200 ml of vehicle solution). The recipe for the vehicle solution was 10% (v/v) ethanol, 0.1% (v/v) acetic acid, 40% (v/v) PEG-400 (polyethylene glycol, molecular weight 400), and 0.05% (w/v) O-carboxymethylcellulose. Glucose and weight measurements were taken at 3:00 p.m., after 6 hours of food withdrawal. GTTs were performed by intraperitoneal glucose injection (1 g/kg) after an overnight food withdrawal as described previously (18) . Metabolic cage and euglycemic hyperinsulinemic clamp studies were performed as described previously (70, 71) .
Islet isolation
The methods for isolating islets from mice were described previously (69) . Briefly, the pancreatic duct was perfused with 2.5 ml of Liberase RI (3 mg/ml) (Roche), after which it was excised and then disaggregated by shaking for 24 min at 37°C. The islets were partially isolated by sedimentation and then handpicked from the acinar tissue debris under a dissecting microscope.
Statistical analysis
Graphical data are presented as means ± SEM or SD as indicated in the figure legends. Differences between groups were determined by Student's t test or repeated-measures ANOVA as indicated and considered significant when P < 0.05. Data were normally distributed.
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